Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).
Melissa BersanelliSebastiano ButiAlessio CortelliniMarco BandiniGiuseppe Luigi BannaFilippo PederzoliElena FarèDaniele RaggiPatrizia GiannatempoUgo De GiorgiUmberto BassoTania LosannoDaniele SantiniClaudia MucciariniMarcello TucciRosa TambaroAzzurra FarnesiOrazio CaffoAntonello VecciaEmanuele NaglieriAlberto BrigantiGiuseppe ProcopioSandro PignataAndrea NecchiPublished in: Clinical Medicine Insights. Oncology (2021)
Chemotherapy administered after ICI progression for mUC patients is advisable irrespective of the treatment line.